Vaccines Market Size & Share, by Type (Inactivated, Recombinant, Live Attenuated, Toxoid); Administration Route (Oral, Parenteral); Age Group (Adults, Pediatric); Application {Viral Diseases (Influenza, Hepatitis, Herpes Zoster, Rubella, Rotavirus), Bacterial Diseases (Diphtheria, Meningococcal, Pneumococcal)}; Distribution Channel (Government Supplier, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Request Free Sample Copy

Report ID: 1399
Published Date: Feb 06, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Vaccines Landscape

GlaxoSmithKline plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Pfizer Inc.
Sanofi Aventis
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Bavarian Nordic A/S
Novartis AG
Inovio Pharmaceuticals, Inc.
CSL Limited
Emergence BioSolutions, Inc.

Browse Key Market Insights with Data Illustration:

Vaccines Market Size & Share, Growth Forecasts 2033

In the News

Pfizer Inc. to reveal the positive results from the Phase 3 study that has been recently conducted. The data from the study defines the 20-valent pneumococcal conjugate vaccine candidate. Apart from accomplishing positive results, the vaccine is still on its way to acquiring approval from requisite agencies.
GlaxoSmithKline plc to acquire prequalification from the World Health Organization (WHO) Mosquirix, additionally known as RTS, S/AS01. With this accomplishment, Mosquirix becomes the only approved vaccine for malaria. Furthermore, the vaccine I ready to be rolled out in the countries with a higher prevalence of P. falciparum malaria transmission.

Frequently Asked Questions (FAQ)

Growing demand for vaccines to cure hepatitis b and increasing cases of tuberculosis across the globe are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2033.

The requirement for higher initial investment and long-lasting and costly procedure of R&D of the vaccine is estimated to challenge the market growth.

The market in the Asia Pacific is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Sanofi Aventis, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Bavarian Nordic A/S, Novartis AG, Inovio Pharmaceuticals, Inc., CSL Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, administration route, age group, application, distribution channel, and by region.

The bacterial diseases segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Companies Dominating the Vaccines Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the vaccines market?

What would be the CAGR of vaccines market over the forecast period?

What are the challenges affecting the vaccines market growth?

Which region will provide more business opportunities for growth of vaccines market in future?

Who are the major players dominating the vaccines market?

How are the company profiles selected?

What are the segments in the vaccines market?

Which segment captures the largest market size in application in the vaccines market?